GlassScriptPhysician profile
Gregory A Berland
NPI 1265427405
$6,699.91
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,005 · 2020: $1,622 · 2021: $760 · 2022: $496 · 2023: $1,372 · 2024: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,789 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,789.02 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,187.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $722.05 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $509.70 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $450.20 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $391.14 | 2019-2021 | |
| Astellas Pharma US INC | $348.51 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $269.68 | 2019-2024 | Trelegy Ellipta |
| Lilly USA, LLC | $257.32 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $216.67 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $204.61 | 2019-2024 | Airsupra |
| Amgen INC. | $193.56 | 2021-2024 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $177.12 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.82 | 2019-2024 | Trintellix |
| Scilex Pharmaceuticals INC. | $160.55 | 2023-2024 | Ztlido |
| Dexcom, INC. | $159.86 | 2021-2024 | Dexcom G6 Transmitter |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Berland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.